Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Journal: Rheumatology and therapy
Published: April 03, 2019
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 23, 2016
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 15, 2016
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
Journal: The Journal of rheumatology
Published: January 17, 2014
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
Journal: Annals of the rheumatic diseases
Published: December 26, 2013
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Journal: Annals of the rheumatic diseases
Published: June 26, 2012
Showing 1-6 of 6
Last Updated: 09/26/2026